Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options
Bebtelovimab continues to maintain neutralization activity against all known variants of interest and concern. VANCOUVER, BC — AbCellera (Nasdaq: ABCL) today announced that Eli Lilly and Company (Lilly) has entered into… Read More




